Iss Pharmaceuticals Inc is categorized under Commercial Medical Research in Bethlehem, PA and active since 2001.
Iss Pharmaceuticals Inc was established in 2001, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Bhupinder S Madan at the company’s single location by writing to 116 Research Drive, Bethlehem, Pennsylvania PA 18015 or by phoning (610) 849-5030. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Iss Pharmaceuticals Inc |
| Contact Person: | Bhupinder S Madan |
| Address: | 116 Research Drive, Bethlehem, Pennsylvania 18015 |
| Phone Number: | (610) 849-5030 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2001 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Iss Pharmaceuticals Inc was started in 2001 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Bhupinder S Madan for inquiries that concern Iss Pharmaceuticals Inc by calling the company number (610) 849-5030, as your correspondence is most welcome. Additionally, the physical location of the single location of Iss Pharmaceuticals Inc can be found at the coordinates 40.601453,-75.363354 as well as the street address 116 Research Drive in Bethlehem, Pennsylvania 18015.
For its online presence, you may visit Iss Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.